ME 23andMe
- 0.530
- -0.017-3.04%
- 0.550
- +0.020+3.75%
23andMe News
Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading
Health care stocks were decreasing Tuesday afternoon, with the NYSE Health Care Index fractionally lower and the Health Care Select Sector SPDR Fund (XLV) down 0.1% The iShares Biotechnology ETF (IBB)
23andMe Unit Offers Petros Pharmaceuticals' Impotency Medication
23andMe Holding (ME) unit Lemonaid Health now offers Petros Pharmaceuticals' (PTPI) prescription erectile dysfunction drug Stendra through its telehealth platform, the company said Tuesday. 23andMe sh
Lemonaid Health Now Offers Prescription ED Medication STENDRAR Through Collaboration With Petros Pharmaceuticals
Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activitySUNNYVALE, Calif., May 14, 2024 (GLOBE NE
Alibaba cleared site B and opened positions on Zhihu in the first quarter, and the total market value of US stock holdings fell 63%
According to the US Securities and Exchange Commission (SEC) disclosure, Alibaba submitted a US stock position report (13F) for the first quarter ended March 31, 2024.
Struggling 23andMe Granted Extension to Revive Stock Price
23andMe to Report Q4 and Full Year FY2024 Financial Results
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access,
23andMe(ME.US) Officer Sells US$19,048.05 in Common Stock
$23andMe(ME.US)$ Officer HIBBS KATHY L sold 38,551 shares of common stock on May 2, 2024 at an average price of $0.4941 for a total value of $19,048.05.Source: Announcement What is statement of change
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced that two abstracts on 23ME-00610, a first-in-class anti-CD200R1 antibody, have been accepted for poster presentations at the 2024 ASCO Annual Meeting, taking place May 31 - June 4 in Chicago.
Petros, Lemonaid Health Collaborate to Expand Stendra Availability
Petros Pharmaceuticals (PTPI) said Tuesday that it is collaborating with Lemonaid Health to provide Stendra, a prescription medication for erectile dysfunction, via Lemonaid's telehealth platform. Lem
23andMe(ME.US) Officer Sells US$18,148.4 in Common Stock
$23andMe(ME.US)$ Officer HIBBS KATHY L sold 38,548 shares of common stock on Apr 18, 2024 at an average price of $0.4708 for a total value of $18,148.4.Source: Announcement What is statement of change
23andMe CEO Anne Wojcicki Says She's Weighing Buyout Bid -- Barrons.com
By Eric J. Savitz In what looks like a potentially downbeat ending to 23andMe's journey as a public company, founder and CEO Anne Wojcicki has offered to take the DNA testing business private. Wojci
US stocks closed | S&P and NASDAQ fell five times in a row, and Tesla fell more than 3% to close at a 15-month low
The Dow rebounded slightly, leading share gains on the third day after the UnitedHealth earnings report; TSMC's results later fell nearly 5%.
Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup
Health-care companies were flat as traders rotated into sectors less sensitive to moves in interest rates. Anne Wojcicki is seeking to take her DNA-testing company 23andMe private after three years i
Sector Update: Health Care Stocks Ease in Afternoon Trading
Health care stocks eased Thursday afternoon with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both 0.1% lower. The iShares Biotechnology ETF (IBB) fell 0.7%. In corpora
Sector Update: Health Care
Health care stocks were easing Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both 0.1% lower. The iShares Biotechnology ETF (IBB) fell 0.7%. In
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Las Vegas Sands Corp. (NYSE:LVS) fell sharply during Thursday's session despite better-than-expected first-quarter results.The company reported quarterly adjusted earnings of 75 cents per sh
Changes in US stocks: 23andMe once rose more than 44%, CEO considering privatization
GLONGHUI, April 18 | Consumer genetics research company 23andMe Holding Co., US stocks rose more than 44.58% at the beginning of the market, which is expected to end the previous six-day decline and report at $0.5150, breaking away from the intraday low of $0.35 since the US IPO in June 2021. Anne Wojcicki, CEO of the DNA testing company, told board members that she is considering privatizing the struggling company.
23andMe Up Over 43%, on Track for Record Percent Increase -- Data Talk
23andMe Holding Co. Class A (ME) is currently at $0.51, up $0.15 or 43.21% --Would be highest close since April 3, 2024, when it closed at $0.52 --Would be largest percent increase on record (Based
23andMe Stock Jumps on News of Plans to Take It Private -- WSJ
By WSJ Staff Shares of 23andMe jumped Thursday on the news that the DNA-testing company's chief executive plans to take it private. 23andMe's stock was recently up nearly 35%. Anne Wojcicki's intent
23andMe Forms Special Committee for Strategic Governance
Analysis
Price Target
No Data
